DPP4i have no intrinsic glucose-lowering activity, so their efficacy as anti-diabetic agents is related directly to their ability to inhibit DPP4 activity and is mediated through the effects of the substrates they protect
The balance and coordination issues that severe deficiency can cause raise the risk of falls, which is a focus of our geriatric care
However, the structurally modified version of the tetra-substituted peptide, Modified GRF 1-29, is considered to boast a longer half-life and has, therefore, been considered by researchers as a more viable compound for use during experimental research
For these reasons, the FDA-approved versions (Ozempic, Wegovy, Mounjaro, Zepbound) require a prescription
The FDA prescribing information includes pancreatitis as a warning for semaglutide
No randomized controlled trial has studied microdosing tirzepatide specifically